Will Manufacturing Issues Hobble Abatacept?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's decision to push back the user fee date for Bristol-Myers Squibb's rheumatoid arthritis therapy Orencia (abatacept) could have a ripple effect on the launch of the product